The firm is in the midst of evaluating its strategic options and has hired Raymond James to assist in the process, which could include the sale of the firm, it said.
The company has highlighted the study as evidence that its test would outperform Roche's FDA-approved liquid biopsy assay if implemented in the clinic.
The privately held Cambridge, UK-based company announced earlier this month that it had raised an additional £11 million to support the commercialization of its platform.
The financing will be used by the company to bring its breath-based diagnostic technology to market, fund clinical trials, and grow its precision medicine services.
The company plans to launch an RNA sequencing-based test to help subtype and determine treatment for thyroid cancer, and a test to detect noninvasive lung cancer.
The companies will work together to develop a series of cancer screening tests that employ Preora's cytology platform and its sample-preparation technologies.
